Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia

NCT02274558 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT02274558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
July 31, 2016
Enrollment
234 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

tardive dyskinesia